Loading
Inflammasome and Immune Disorders / Adipokines, Inflammation, and Metabolic Diseases · Journal article
International Journal of Molecular Sciences · September 10, 2026
Raises a question worth testing. It does not answer one.
This narrative review synthesises current understanding of bidirectional coupling between immune and metabolic signalling in obesity-associated type 2 diabetes, proposing a mechanistic chain from nutrient excess through inflammasome activation to beta-cell dysfunction. The authors emphasize a central unresolved question: why sustained IL-1β neutralisation reduced cardiovascular events without preventing incident diabetes, framing this dissociation as the critical challenge for immunometabolic therapeutics in T2D.
Narrative review. Individuals with obesity-associated type 2 diabetes; review acknowledges heterogeneity across recognised disease subgroups..
Nutrient excess drives glucolipotoxic stress engaging innate immune sensors in adipose tissue, liver, skeletal muscle and pancreatic islets. Metabolites succinate and itaconate specify inflammatory output and converge on NLRP3 inflammasome assembly and IL-1β release, interrupting insulin signalling. Sustained IL-1β neutralisation reduced cardiovascular events without preventing incident diabetes, indicating a dissociation that constrains the field.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize T2D as a chronic low-grade inflammatory disease with coupled immune–metabolic signalling. The unresolved dissociation between IL-1β neutralisation efficacy on cardiovascular outcomes versus diabetes incidence suggests current immunometabolic targeting strategies may require refinement or patient stratification.
This is a narrative review synthesising mechanistic pathways in obesity-associated T2D without reporting original empirical data, primary endpoints, or comparative trials; it raises questions about immunometabolic mechanisms rather than answering them with quantified evidence.
As stated by the source record.
Clinicians should recognize T2D as a chronic low-grade inflammatory disease with coupled immune–metabolic signalling. The unresolved dissociation between IL-1β neutralisation efficacy on cardiovascular outcomes versus diabetes incidence suggests current immunometabolic targeting strategies may require refinement or patient stratification.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Type 2 diabetes (T2D) is increasingly understood as a chronic, low-grade inflammatory disease in which immune and metabolic signalling are bidirectionally coupled. Nutrient excess drives glucolipotoxic stress in adipose tissue, liver, skeletal muscle and pancreatic islets, engaging innate immune sensors. Responding immune cells then reconfigure their own intermediary metabolism, and the resulting metabolites—succinate, which stabilises hypoxia-inducible factor-1α, and the itaconate that opposes it—themselves specify inflammatory output. These signals converge on NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome assembly, gasdermin D-mediated pyroptosis and interleukin-1β (IL-1β) release, which interrupt insulin signalling through inhibitory serine phosphorylation of insulin receptor substrate-1. Mitochondrial dysfunction, impaired mitophagy and cytosolic mitochondrial DNA sensing sustain the loop, while gut barrier failure supplies a parallel systemic input that converges on beta-cell dysfunction. This narrative review synthesises these mechanisms and examines how metformin, glucagon-like peptide-1 receptor agonists, sodium–glucose cotransporter 2 inhibitors and inflammasome-directed agents intersect with them. The chain described is that of obesity-associated T2D, and the heterogeneity that limits its generalisation across the recognised subgroups of the disease is addressed explicitly rather than assumed away. We give particular weight to a dissociation that constrains the field: sustained IL-1β neutralisation reduced cardiovascular events without preventing incident diabetes. Establishing why is, in our view, the central question for immunometabolic therapeutics in T2D.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.